Hormonal
The novel long-acting glucagon analogue HM15136 causes dose-dependent fasting plasma glucose elevation and mild weight loss in overweight/obese patients, with hyperglycemia limiting tolerability at higher doses (0.06 mg/kg) in patients with Type 2 Diabetes.
HM15136 is a weekly injection that causes mild weight loss (approx 2-3%) but significantly raises blood sugar. It is not recommended for obesity treatment, especially for those with Type 2 Diabetes, due to safety concerns regarding hyperglycemia. It may be explored for chronic hypoglycemia or in combination with other drugs.
Dose-dependent increases in mean HM15136 serum concentration and fasting plasma glucose (FPG) were observed, as were dose-dependent weight reductions of 0.5%/2.3%/2.6% at doses of 0.02/0.04/0.06 mg/kg, respectively... The 0.06 mg/kg dose was not tolerated in part 2 because of hyperglycaemia.
Why this rating
Phase 1 trial, small sample sizes (n=27 and n=12), short duration (12 weeks), but double-blind and placebo-controlled.
Source
Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long‐acting glucagon analogue <scp>HM15136</scp> in overweight and obese patients with co‐morbidities
Wonjung Shin et al. · Diabetes Obesity and Metabolism · 2023
DOI 10.1111/dom.15162
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →